Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514943 · ClinicalTrials.gov registry record · Phase 2
BIBW 2992 (Afatinib) in Head & Neck Cancer
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00514943 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 124 participants.
The verdict
NCT00514943, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy. In addition, the trial aims to clarify the influence of EGFR genotype on tumor response to the treatment regimens.
Interventions
- DRUG Cetuximab
- DRUG BIBW 2992
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514943
The ClinicalTrials.gov registry entry for NCT00514943 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT00514943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00514943 about?
NCT00514943 is a clinical study titled "BIBW 2992 (Afatinib) in Head & Neck Cancer". The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy. In addition, the trial aims to clarify the influence of EGFR genotype on tumor res...
What is the current status of trial NCT00514943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2007-08. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00514943?
The interventions under investigation include: Cetuximab (DRUG), BIBW 2992 (DRUG).
Who is sponsoring clinical trial NCT00514943?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.